Quick Takeaways Why It Matters? Liavium-CA1 gives Pegasus (PRN Pharmacal) a first-in-class, branded neurology asset in a completely underserved niche, which should support premium pricing and strong loyalty among neurologists and specialty practices that see CM/SM dogs. B...
Quick Takeaways Why It Matters? Befrena gives Elanco a direct challenger to Zoetis’ Cytopoint in the fast‑growing canine allergy biologics market, with a slightly longer recommended dosing interval (every 6–8 weeks vs 4–8 weeks) and no age or weight limits...
Quick Takeaways: Why It Matters? This launch is Yuyu Pharma’s first real step into the US pet health market, using Amazon as a low‑barrier, high‑visibility channel to test its cat wellness offering and build brand awareness under the Mervyn’s Petcare label. If Ari’s...
Quick Takeaways Why It Matters? VetSnap’s new 2‑Bay Smart Locker gives small and mobile veterinary practices a lower-cost way to get DEA‑compliant, automated storage and tracking for controlled drugs, instead of relying on basic safes and paper logs. By pricing...
Quick Takeaways Why It Matters? This Petco rollout gives Fera Pets a much bigger retail stage and moves its vet-founded, “clean-label” supplements from niche online channels into mainstream, in‑store traffic. This move will raise competitive pressure on legacy suppl...
Quick Takeaways Why It Matters? This GRAS clearance gives Hill’s and Bond a first‑mover, “next‑gen” animal protein that can start showing up in premium dog foods as a sustainable, precision‑fermented alternative to conventional lamb. From a market an...
Quick Takeaways Why It Matters? A new proprietary CNS asset from Orion, exclusively commercialized by Zoetis in the US, that taps into fast‑growing demand for medical management of canine anxiety and should expand the addressable market beyond situational noise phobia toward mo...
Quick Takeaways Why It Matters? Ceva is using this JV to turn Japan from a peripheral presence into a true platform market, bolting its global livestock and pet portfolio onto Bussan Animal Health’s 75‑year brand, field force, and ~€40M business to create a full‑line ...
Quick Takeaways: Why It Matters? Volition is positioning Nu.Q Vet Feline as a potential first scalable, affordable blood test for feline lymphoma, with performance (86% sensitivity at 97% specificity) strong enough to support real-world screening, not just “rule...
Quick Takeaways Why It Matters? Gallant is on track to create one of the first mass‑market, disease‑modifying OA biologics in companion animals, shifting regenerative medicine from niche referral centers into everyday general practice via a simple, ready‑to‑use IV product. ...
